⌘K
Loading ticker…
Bicara Therapeutics Inc. Common Stock · Healthcare · Pharmaceutical Products
As of 2026-06-26, Bicara Therapeutics Inc. Common Stock (BCAX) has a 3-month relative strength percentile of 87 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 78. The current market Stance is 47 (Neutral). Sector: Healthcare. Average daily range 5.7%, relative volume 6.90×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
3m RS is 87, Market Stance is mixed at 47, A/D rating A
YoY sales growth, last 8 quarters. Sales must back the earnings story.
Operating margin unavailable
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
Daily range, ATR, beta, and the math for a 1-ADR stop.
BCAX is in a stage 2 uptrend, week 2. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: 21.4% / 47.5%.
Strong relative strength, but attention is quiet relative to this name’s own recent norm. Academic work links low public attention to better forward returns on average — context to weigh, not a forecast.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
News
Related searches
BCAX is held by 6 ETFs as of Mar 2026. Top owner: VTI at 0.00% weight, $27M notional. Top 3 carry $57M.
Top 6 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value |
|---|---|---|
| VTIVanguard Total Stock Market ETF | 0.00% | $27M |
| IWMiShares Russell 2000 ETF | 0.02% | $16M |
| XBIState Street SPDR S&P Biotech ETF | 0.19% | $14M |
| VXFVanguard Extended Market ETF | 0.01% | $7M |
| ITOTiShares Core S&P Total U.S. Stock Market ETF | 0.00% | $981K |
| IWOiShares Russell 2000 Growth ETF | 0.00% | $250K |
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | BCAX Jan avg: -13.87% median: -13.87% win: 0% σ: 19.36% n: 2 2024-09-16 → 2026-05-29 | BCAX Feb avg: 2.63% median: 2.63% win: 50% σ: 3.89% n: 2 2024-09-16 → 2026-05-29 | BCAX Mar avg: 8.25% median: 8.25% win: 50% σ: 14.54% n: 2 2024-09-16 → 2026-05-29 | BCAX Apr avg: 9.39% median: 9.39% win: 100% σ: 1.26% n: 2 2024-09-16 → 2026-05-29 | BCAX May avg: -17.42% median: -17.42% win: 50% σ: 25.75% n: 2 2024-09-16 → 2026-05-29 | BCAX Jun avg: 0.43% median: 0.43% win: 100% σ: 0.00% n: 1 2024-09-16 → 2026-05-29 (current) | BCAX Jul avg: 19.59% median: 19.59% win: 100% σ: 0.00% n: 1 2024-09-16 → 2026-05-29 | BCAX Aug avg: 7.47% median: 7.47% win: 100% σ: 0.00% n: 1 2024-09-16 → 2026-05-29 | BCAX Sep avg: 20.52% median: 20.52% win: 100% σ: 16.58% n: 2 2024-09-16 → 2026-05-29 | BCAX Oct avg: -2.06% median: -2.06% win: 50% σ: 7.03% n: 2 2024-09-16 → 2026-05-29 | BCAX Nov avg: 1.00% median: 1.00% win: 50% σ: 18.68% n: 2 2024-09-16 → 2026-05-29 | BCAX Dec avg: -12.77% median: -12.77% win: 0% σ: 4.87% n: 2 2024-09-16 → 2026-05-29 |